Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study Meeting Abstract
| Authors: | Sharman, J. P.; Brander, D. M.; Mato, A. R.; Ghosh, N.; Schuster, S. J.; Kambhampati, S.; Burke, J. M.; Lansigan, F.; Schreeder, M. T.; Lunin, S. D.; Zweibach, A.; Shtivelband, M.; Travis, P. M.; Chandler, J. C.; Kolibaba, K. S.; Sportelli, P.; Miskin, H. P.; Weiss, M. S.; Flinn, I. |
| Abstract Title: | Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368303242 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.8022 |
| Notes: | Meeting Abstract: 8022 -- Source: Wos |
